Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Soundtec Direct System

This article was originally published in The Gray Sheet

Executive Summary

Implantable hearing device PMA approved by FDA Sept. 7 for use in adults who have a moderate-to-severe sensorineural hearing loss and who desire an alternative to an acoustic hearing aid. Postapproval reports must include: clinically significant changes in residual hearing to the implant ear; alleged complications due to ossicular erosion; and device extrusions. The Oklahoma City firm's device consists of a speech/sound processor worn in or behind the ear and a tiny rare-earth magnet implanted in the middle ear in a procedure taking 25 minutes that be performed under local anesthetic

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel